Literature DB >> 3658161

Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study.

H P Adams1, N F Kassell, J C Torner, E C Haley.   

Abstract

Cerebral ischemia from vasospasm is a major cause of death and disability following aneurysmal subarachnoid hemorrhage (SAH). This study examines and compares the relative utility of the initial neurologic examination and early CT in predicting cerebral ischemia after SAH. The influence of antifibrinolytic drugs (AFD) in the development of cerebral ischemia was also studied. AFD increased the risk of cerebral ischemia regardless of the admitting neurologic condition or the findings of CT. Among patients given AFD, impaired orientation or alertness was associated with a higher risk of ischemia. Other neurologic signs were not predictive of ischemia. Clinical features were not predictive of ischemia among patients not given AFD. Focal, thick collections of blood on CT were highly predictive of ischemia, whether or not patients received AFD. Admitting CT is the best prognostic indicator for the development of cerebral ischemia after SAH. It should be used to supplement the clinical examination in selecting patients best suited for therapy to prevent vasospasm.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3658161     DOI: 10.1212/wnl.37.10.1586

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  50 in total

1.  Treatment of subarachnoid hemorrhage with human albumin: ALISAH study. Rationale and design.

Authors:  Jose I Suarez; Renee H Martin
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

2.  MR angiography in patients with subarachnoid hemorrhage: adequate to evaluate vasospasm-induced vascular narrowing?

Authors:  Elke Hattingen; Stella Blasel; Richard Dumesnil; Hartmut Vatter; Friedhelm E Zanella; Stefan Weidauer
Journal:  Neurosurg Rev       Date:  2010-06-08       Impact factor: 3.042

3.  The safety and feasibility of continuous intravenous magnesium sulfate for prevention of cerebral vasospasm in aneurysmal subarachnoid hemorrhage.

Authors:  Abutaher M Yahia; Jawad F Kirmani; Adnan I Qureshi; Lee R Guterman; L Nelson Hopkins
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Subarachnoid hemorrhage in the African-American population: a cooperative study.

Authors:  G C Dennis; B Welch; A N Cole; R Mendoza; J Morgan; J Epps; E Bernard; P St Louis
Journal:  J Natl Med Assoc       Date:  1997-02       Impact factor: 1.798

Review 5.  Artificial Intelligence in the Management of Intracranial Aneurysms: Current Status and Future Perspectives.

Authors:  Z Shi; B Hu; U J Schoepf; R H Savage; D M Dargis; C W Pan; X L Li; Q Q Ni; G M Lu; L J Zhang
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-12       Impact factor: 3.825

Review 6.  Changing practices in neuroanaesthesia.

Authors:  J C Drummond
Journal:  Can J Anaesth       Date:  1990-05       Impact factor: 5.063

Review 7.  Aneurysmal subarachnoid hemorrhage: prevention of delayed ischemic dysfunction with intravenous nimodipine.

Authors:  B Ljunggren; L Brandt; H Säveland; B Romner; T Ryman; K E Andersson
Journal:  Neurosurg Rev       Date:  1987       Impact factor: 3.042

8.  Outcome of patients with aneurysmal and presumed aneurysmal bleeding. A hospital study based on 100 consecutive cases in a neurological clinic.

Authors:  H Schütz; P Krack; B Buchinger; R H Bödeker; A Laun; W Dorndorf; A Agnoli
Journal:  Neurosurg Rev       Date:  1993       Impact factor: 3.042

Review 9.  Vasodilators during cerebral aneurysm surgery.

Authors:  K Abe
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

10.  Genes influencing coagulation and the risk of aneurysmal subarachnoid hemorrhage, and subsequent complications of secondary cerebral ischemia and rebleeding.

Authors:  Ynte M Ruigrok; Arjen J C Slooter; Gabriel J E Rinkel; Cisca Wijmenga; Frits R Rosendaal
Journal:  Acta Neurochir (Wien)       Date:  2009-10-14       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.